Podcasts about Agrawal

Can you truly engage students in active learning when facing hundreds of faces in a lecture hall? We explore this challenge with Justin Shaffer, Founder of Recombinant Education, Associate Dean for Undergraduate Studies, and Teaching Professor in Chemical and Biological Engineering and Quantitative Biosciences and Engineering at the Colorado School of Mines.Dr. Shaffer shares insights on managing the intensity of teaching to "880 eyeballs" and reveals how highly structured course design transforms large classroom experiences. Together, we examine backwards design principles, effective assessment techniques, and practical classroom activities that enable educators to foster deeper student learning, even at scale.Learn more about Dr. Shaffer's work in his publication - High Structure Course Design.Other materials referenced in this episode include:S. Freeman, S.L. Eddy, M. McDonough, M.K. Smith, N. Okoroafor, H. Jordt, & M.P. Wenderoth, Active learning increases student performance in science, engineering, and mathematics, Proc. Natl. Acad. Sci. U.S.A. 111 (23) 8410-8415, https://doi.org/10.1073/pnas.1319030111 (2014).E.J. Theobald, M.J. Hill, E. Tran, S. Agrawal, E.N. Arroyo, S. Behling, N. Chambwe, D.L. Cintrón, J.D. Cooper, G. Dunster, J.A. Grummer, K. Hennessey, J. Hsiao, N. Iranon, L. Jones, H. Jordt, M. Keller, M.E. Lacey, C.E. Littlefield, A. Lowe, S. Newman, V. Okolo, S. Olroyd, B.R. Peecook, S.B. Pickett, D.L. Slager, I.W. Caviedes-Solis, K.E. Stanchak, V. Sundaravardan, C. Valdebenito, C.R. Williams, K. Zinsli, & S. Freeman, Active learning narrows achievement gaps for underrepresented students in undergraduate science, technology, engineering, and math, Proc. Natl. Acad. Sci. U.S.A. 117 (12) 6476-6483, https://doi.org/10.1073/pnas.1916903117 (2020).M.T. Owens, S.B. Seidel, M. Wong, T.E. Bejines, S. Lietz, J.R. Perez, S. Sit, Z. Subedar, G.N. Acker, S.F. Akana, B. Balukjian, H.P. Benton, J.R. Blair, S.M. Boaz, K.E. Boyer, J.B. Bram, L.W. Burrus, D.T. Byrd, N. Caporale, E.J. Carpenter, Y.M. Chan, L. Chen, A. Chovnick, D.S. Chu, B.K. Clarkson, S.E. Cooper, C. Creech, K.D. Crow, J.R. de la Torre, W.F. Denetclaw, K.E. Duncan, A.S. Edwards, K.L. Erickson, M. Fuse, J.J. Gorga, B. Govindan, L.J. Green, P.Z. Hankamp, H.E. Harris, Z. He, S. Ingalls, P.D. Ingmire, J.R. Jacobs, M. Kamakea, R.R. Kimpo, J.D. Knight, S.K. Krause, L.E. Krueger, T.L. Light, L. Lund, L.M. Márquez-Magaña, B.K. McCarthy, L.J. McPheron, V.C. Miller-Sims, C.A. Moffatt, P.C. Muick, P.H. Nagami, G.L. Nusse, K.M. Okimura, S.G. Pasion, R. Patterson, P.S. Pennings, B. Riggs, J. Romeo, S.W. Roy, T. Russo-Tait, L.M. Schultheis, L. Sengupta, R. Small, G.S. Spicer, J.H. Stillman, A. Swei, J.M. Wade, S.B. Waters, S.L. Weinstein, J.K. Willsie, D.W. Wright, C.D. Harrison, L.A. Kelley, G. Trujillo, C.R. Domingo, J.N. Schinske, & K.D. Tanner, Classroom sound can be used to classify teaching practices in college science courses, Proc. Natl. Acad. Sci. U.S.A. 114 (12) 3085-3090, https://doi.org/10.1073/pnas.1618693114 (2017).A.M. Hermundstad, D.S. Bassett, K.S. Brown, E.M. Aminoff, D. Clewett, S. Freeman, A. Frithsen, A. Johnson, C.M. Tipper, M.B. Miller, S.T. Grafton, & J.M. Carlson, Structural foundations of resting-state and task-based functional connectivity in the human brain, Proc. Natl. Acad. Sci. U.S.A. 110 (15) 6169-6174, https://doi.org/10.1073/pnas.1219562110 (2013).

Actor, comedian, and content creator Aanchal Agrawal joins Cyrus for a hilarious and heartfelt episode — from MBA and NYU to acting school, viral reels, and why her content connects so strongly with women. In this episode, Cyrus and Aanchal dive into:-How she switched careers from MBA → NYU → corporate → acting → comedy-The story of her viral “Ameer kaise lage” reel and how people still share it-Her thoughts about marriage (and what her followers think!)-NYU life, high tax brackets, and choosing comedy over the safe path.-Building All Women INC, her women-first media project.-Dating stories, poolside luxury jokes, and much more…See omnystudio.com/listener for privacy information.

Dhruv Agrawal is CEO and president of Aether Biomedical. Discover Dhruv's unique journey from studying medicine in New Delhi to creating life-changing bionic limbs. Under his leadership, Aether Biomedical has achieved significant milestones, including CE certification and FDA registration for its Zeus V1 bionic limb. Dhruv shares his personal story of transitioning from medical school to MedTech innovation, the obstacles faced and lessons learned as a young entrepreneur, and the hope and inspiration of seeing Aether's prosthetics transform lives, especially in war-torn regions.   Guest links: https://www.aetherbiomedical.com | https://www.linkedin.com/company/aether-biomedical | https://www.instagram.com/aether_biomedical/  Charity supported: ASPCA Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 061 - Dhruv Agrawal Dhruv Agrawal [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and today I'm excited to introduce you to my guest, Dhruv Agrawal. Dhruv is the CEO and president of the management board of Aither Biomedical. He studied medicine in New Delhi before dropping out to pursue a bachelor's in business management. He also has a postgraduate diploma in Medical Device Development Regulatory Affairs from University of California Irvine, and a Master's in Data Science from the University of London. Under his leadership, Aither Biomedical has achieved CE certification and FDA registration for the Zeus V1 bionic limb, and established distribution across nine European countries, the US, and India. Additionally, Aither has raised over 12.5 million US dollars in private capital from leading VCs and has been a part of multiple European grants and research programs for an additional 6.5 million US dollars in non-dilutive capital. All right. Well, thank you so much for being here. Welcome to the show. I'm so excited to speak with you today. [00:01:49] Dhruv Agrawal: it's a pleasure to be here, Lindsey. Thank you so much for inviting me. [00:01:52] Lindsey Dinneen: Of course, of course. Well, I would love, if you wouldn't mind just starting by sharing a little bit about yourself and your background and what led you to Med Tech. [00:02:02] Dhruv Agrawal: Yeah, absolutely. So I'm Dhruv Agrawal. I'm the CEO of Aither Biomedical. We are a company based out of Poznan in Poland, so on the western part of Poland. It's a little bit chilly here. As a company, we are a team of about 55 people right now, currently present in the US, Europe, Middle East, as well as India. And we focus on making bionic hands for upper limb amputees. [00:02:25] Lindsey Dinneen: Amazing. Yes. So I wanna get into everything amazing that your company does, but going back for just a little bit, in your own personal history, can you share a little bit about maybe growing up and what experiences led you to think, "Hey, in the future, maybe I wanna do X, Y, and Z." [00:02:43] Dhruv Agrawal: Mm-hmm. So first of all, entrepreneurship was never a plan for me. I didn't even knew that there was a thing called an entrepreneur until I was easily into high school. Both my parents are doctors. My dad's a pediatrician, mom's a gynecologist, and as it happens in India, if your parents are doctors, you kind of know that you have to become a doctor as well. So I went to the coaching classes to pre, to prepare for medical entrance examinations. I actually met my co-founder there about 10 years ago. We both got into medical school. I was generally comfortable with medicine, you know, growing up in a hospital with doctor parents around. So I was generally comfortable in a clinical setting, but I realized that I was much more interested in the technological aspect of medicine rather than the clinical aspect of it. And that was when I was getting into the second year of my university. And luckily my dad, for my 18th birthday, bought me a 3D printer, like a very simple 3D printer from China as my 18th birthday gift. 'cause I was really wanting to get into that world. And that's where the story begins. So even till today, my dad jokingly says that that's the worst gift he has ever bought for me, because that made me drop out of medical school. [00:03:57] Lindsey Dinneen: Oh no. Okay, so you were given this gift and you started, I imagine, tinkering with it, learning how to use it. So tell me about that. [00:04:06] Dhruv Agrawal: Yeah, the thing with my co-founder as well, even though we went to the same medical university, we were not really friends in the first year. We were just colleagues. But when I got this 3D printer, it was like one of those things that you assemble, you get a kit and you assemble. And I was asking around people in my university and they were like, "Come on, what are you doing? Like, I don't wanna come to your apartment to assemble a 3D printer." And my co-founder was the first one who said yes to coming down and assembling that printer with me. So that's how our friendship essentially started in the university, even though we had known each other for three years by that point. And then we started, of course, by very basic things like printing mobile phone covers and key chains and we were just in awe with the fact that I have something in my room, in a studio apartment, where I can just build physical things, right? And this was back in 2018, so 3D printer was not such a consumer product where, you know, if it was of course used in industry, but it was not something that you would imagine having at your home, at least not in India. And then we actually found out that there's a society called Enable, which is an NGO that makes very simple basic prosthetic designs for kids. So we started by printing those and started going to some amputee clinics around and trialing that out with patients, just purely out of technical curiosity. We didn't really had a draw towards amputation, so to speak. We were more driven by the technical curiosity of, you know, it sounds interesting to make a prostatic hand. So that was the beginning. And then slowly, slowly things happened very organically that we went from wanting to 3D print basic things to starting a biomedical innovation club in our university, to incorporating a company in India, then to coming all the way over to Poland and now having 55 people. [00:05:49] Lindsey Dinneen: Holy cow. That's an amazing story. Thank you for sharing about that. So, okay, so, so you started off with this curiosity, like, "Hey, let's see what we could do with this printer and, and how we can make it work for people." And I love that your initial pull with it was to actually provide something that does help people. So that's obviously a core value, something that you hold very dear. So can you speak a little bit more, did you have sort of any personal experience or within your family or what led you to say, "You know what, hey, I've got this really cool tool at my disposal. Let me start using it by actually doing something that helps others." [00:06:27] Dhruv Agrawal: I mean, the honest answer, I would love to say I had some personal experience, but the honest answer is no, not, not really. I don't have one of those stories where I can tell you that, like I met an amputee 15 years ago, 20 years ago, and have had that motivation for that time. It was just pure technical curiosity to begin with. But of course, as we started building basic devices and giving it out to people and seeing the response of what a very simple, you know, $50 thing can do for a person who's missing a limb in an impoverished family in a village in India, that's a very powerful thing. So at that point, we realized that we started getting more and more close to upper limb amputation as a field, as a clinical specialty within itself. Of course, both me and my co-founder coming from medical school growing up in family of medicals, we've always had it in our heart to work in the clinical side of things. We've always liked working around, helping people get healthier and better. But amputation specifically was an area that we were very lucky that we found as an area of interest that developed within the both of us. [00:07:31] Lindsey Dinneen: Yeah, of course. Okay, so, so you started printing these limbs, and then you realized, "Oh my goodness, there's such a need for this. There's so much opportunity here to really help people." So, so tell me a little bit about the evolution over time of how you have made it better and better, more technologically advanced, more ergonomic, all the things that go into that. Can you speak a little bit to that learning curve and process? [00:07:56] Dhruv Agrawal: Mm-hmm. Yeah, it was a very long learning curve because not only did, me and my co-founder had zero background in business. We were 18-year-old, 19-year-old kids, right? We were just teenagers and we really had no idea what we wanted to do. And not only that, we also were not engineers, so we didn't have any engineering experience or expertise either. So everything that we did in the very beginning, at least, was self-taught. I just knew I had an inclination towards electronics and programming. My co-founder was much more towards mechanical CAD design and things like that. So we started learning these courses for free on edX and Coursera and all these, you know, MOOC platforms. And that's how we built up the very first prototype of the product by getting some small grants here and there in India. Of course, the situation is very different right now. We have R&D team of 30 people, very experienced, a few PhDs here and there. So I don't really design anymore in my day-to-day life, but that's how we started. And same was the side of the journey of coming from India to Poland. Again, that was not something that was planned at all. We had no experience in business. We had no experience in raising funding or raising money and things like that. We just learned on the go, applied to over a hundred different programs 'cause most of the investors said no to us back then in 2018 to funding 'cause why would they say yes? And we looked at like, "Okay, can we get some grants and things like that?" Applied to over a hundred programs. Luckily got selected in this program in Poland, which was like a $50,000 program back in 2018 and decided, "Yeah, let's try that place out." And came to Poland. I literally came with a backpack with stuff for two months 'cause there was a plan, come for the grant, stay for two months, go back to my family in India, and it's been seven years since then. [00:09:44] Lindsey Dinneen: Oh, there you go. Oh my goodness. That's great. So Poland, and you get along it sounds like just fine. Excellent. Excellent. Okay, so, I really appreciate you sharing about, especially, you were both so young and but so eager. It sounds like just, "Yes, let's learn, let's develop the skills that we need to along the way." I would imagine though, coming into it, perhaps that young and not having as much business experience, or, or any really in, in the past, I-- something that I really admired when I was kind of looking through your LinkedIn profile was when you post, a lot of times you share stories about areas that, that may be considered I, I guess mistakes or stumbling blocks or things that, that you've overcome on your path. And I would love if you would share maybe just a couple of things that come to mind, as an early founder, because your story is amazing and unique, but there are lots of other founders too who find themselves in similar situations where they're like, "Whoof, I've got this great idea. I know what I want, but here's maybe what I should look out for to avoid." could you share a little bit about that? [00:10:49] Dhruv Agrawal: Yeah, absolutely. I mean, the first thing is mistakes are unavoidable, right? it doesn't matter whether you're coming from a background of a medical school dropout, or if you have 10, 15, 20 years of corporate experience and things like that. 'Cause I do find myself thinking a lot about, you know, wouldn't it have been better if I would've graduated and then did a MBA and then started a company? Yes, it might have been better, but the things that I deal with in my day-to-day life in the startup, I don't think this is taught anywhere. So the first and foremost thing, which is of importance, is that mistakes are unavoidable. It's okay to make mistakes. The biggest learning that I have is mistakes are unavoidable, but it's up to you to be decisive enough to pivot as quickly as possible. So don't look back at the mistakes that we have made, because one of the worst things that we have done in this company, or where we have failed the most, or where we have seen that like, "Ah, this is where we could have done things better," are not about making a wrong decision. They were just about being indecisive and being in a dilemma for a long, long time. It would've been far better if we would've made certain decisions quickly, gotten feedback and quickly pivoted, instead of just being in a dilemma and trying to balance two sides for a long time period. An example of that would be when we launched the first version of our product into the market, we realized that we had made some errors from the point of view of what should be the feature set in this product. And so, for example, the product was available only in a medium size hand in terms of the dimensions, but majority of the market is for a small size hand. So at that point we couldn't really just miniaturize things because there's a physical limitation. So at that point we had to make a decision of do we scrap this thing completely and build a new hand from scratch that starts with a small hand and then has a medium sized option as a grow up? Or do we continue to work on the medium sized hand, and then launch a small sized hand separately? Finally, we decided to do the second option. But looking back again, I, I don't think it would've been better or worse either way. I think both of these options are fair. It's just the fact that we spent over nine months going back and forth between, "Okay, let's continue putting our efforts in energy into the medium sized that we have right now" versus, "Okay, this month we are now suddenly feeling, ah, that's not gonna work out. Let's start building the second version." So that dilemma of indecision is probably the worst thing that you can do. Just make a decision, own up to it, move on. If it works out, great, if it not, if it doesn't work out, you're gonna have learnings and you'll be stronger at the end of the day. So that's, I would be an I would say would be an example of one of the key errors that we made. [00:13:23] Lindsey Dinneen: Yeah. Well, thank you for being willing to share that, and that's such valuable advice and feedback. And so, as you recognize this and go, "Okay, so that didn't work as planned, or in the way that I would prefer," what did you end up deciding? How do you go now, moving forward, when you are in a position of "I have a major decision to make. I feel like both options have value and merit." How do you end up deciding, "Okay, I I'm not gonna leave this just in this hazy middle ground, I'm gonna make a decision." How do you go about that now differently? [00:13:54] Dhruv Agrawal: I think the first and foremost thing that entrepreneurs, or anybody who wants to build a new product, or anybody who just wants to build something new, is be very, very, very honest with yourself about, "Am I solving a real problem?" As founders, as creators, as developers, it is so easy to go into that mindset of you find a problem that you can relate to or you somehow think that this is a real problem. It doesn't matter what feedback you're going to get. You're going to convert that feedback, or create a narrative or story from that feedback, that is going to align with the impression that you have built in your own head about what the real problem is. So one thing that we really do right now is just focus on problem market fit at the very early stages of launching a new software, building a new product, building the next version of the hand, or whatever else we do is really try to question, "Are we solving a real problem?" And in a completely unbiased manner, "Do people agree with me that I am solving a real problem?" So that's what I would say would be a primary thing that we do differently right now. Of course at this point, we start getting users involved much earlier into our development process. That is something that we did not do in the past, and hence the surprise that we got at that point. So we start involving users, different stakeholders, and things like that much earlier, but at the same time, I would say that it's not to say that I would penalize myself for the historical decisions that I took. We did the best that we could potentially with the resources that were available at that point. Now we have much more resources so we can do all these things. So don't feel pressured to do everything on day one. You know, start with something, move forward and build that maturity as you grow. [00:15:38] Lindsey Dinneen: Oh, I love that. That's excellent advice. Thank you for sharing. Yeah, so you know that's a great segue and I love the fact that you were talking about the end user and the importance. And it's so funny because of course, ultimately your goal is to help these end users and improve their quality of life and whatnot. But to your point, it does get easy to get so bogged down in the details of what you're creating and innovating that perhaps you forget sort of the bigger picture at times. So, speaking of these end users, can you share any stories that might stand out to you as really reinforcing to you that, "Hey, gosh, I am in the right industry, doing the right thing at the right time." [00:16:17] Dhruv Agrawal: Yeah, no, absolutely. So we have had many phenomenal end users that have reiterated our belief in the product that we are building, the problems that we are solving, the company, and the organization that we are building as a whole. I mean, generally speaking, patients change their devices every three to five years, and that's really our entry point of getting a device into the hands of the patients. But even with those, a patient is using another prosthetic device, they start using ours, they will see a step change in the functionality, and that's always empowering. But the most interesting stories are where we have really seen patients who, for example, congenital amputees tried a prosthetic device 10 years ago, 15 years ago, and then made a decision to live their life without any prosthetic device. So got used to a life for 15, 20, 25 years of living a life without a prosthetic device, just with an amputated limb or a limb difference. And then, we come in with our product, they see it, they use it, and they are ready to adopt that again. And that's a much powerful validation for us because somebody who has used a device, looked at all the advancements over the last two decades, decided actively decided to not use any of those advancements, and looks at our product and says, "Ah, this really solves the problems that I was waiting for someone to solve for the last two decades." Like we had this situation with a very famous Polish guy, Marek Kamiński, who is the youngest Polish person to go to both poles, North Pole and the South Pole, and he's a bilateral amputee on legs and he has a unilateral amputation to one arm. He has not used a prosthetic device in, I think 15 or 20 years, something like that. So for a very long timeframe. He met with an ambassador of ours and was finally convinced after 15 long years to give another try. And we fitted him over three months ago and he's been performing phenomenally with the device and he's so happy with that. So those are the moments that really give us more confidence or give us a boost of confidence in the product that we are building and the company that we are building. [00:18:19] Lindsey Dinneen: That's incredible. Wow. What a story. Yeah, and I love hearing those kinds of stories and that just to reinforce, " Hey, you really are making a difference." And I'm sure that helps on the days that are a little bit harder, a little trickier, you know, it helps to have that to hold onto, so you know your impact goes so far beyond even the places that you've mentioned before. I was reading about how you've worked with the Open Dialogue Foundation and there's been some work in Ukraine, and I'm wondering if you could share a little bit about perhaps that collaboration, and or some of the other exciting collaborations you have going on with these amazing organizations all over the world. [00:18:54] Dhruv Agrawal: Absolutely. I mean, the work that we do in Ukraine is something which is very close to our heart and what you just mentioned a moment ago, it's exactly that type of work that keeps us going on the hardest of days. I have so many amazing stories from the patients who have been fitted with our device 'cause at this point in the last year or so, we have already fitted over a hundred patients with our bionic hands in Ukraine. We primarily work with Superhumans, which is NGO based out of Kyiv, a great place, really the mecca for prosthetics at this point, I would say. They're doing a phenomenal job of getting these patients in, rehabilitating them, fitting them with our device and then training them on how to use the device. In fact, even supporting them in the post rehabilitation, acquainting them to back to the real world as well. And we send teams of doctors from the US, from Poland, to Ukraine to actually fit these devices to patients. And we have had a lot of success stories come out of it. We have people who have amputations, even at the level of shoulder who are amputated all the way up to the shoulder or four quarter amputation, and they are successfully able to live a independent life with our device. I think the best story that I've had, or the part that really made me tear up, was when one of the soldiers got fitted with our device and his really, really big wish was to be able to do the first, to dance with his wife, with both hands. And I got to see that and it was, it was the most amazing feeling ever. [00:20:20] Lindsey Dinneen: Oh my goodness. Yes. I don't know how you couldn't just have the waterfall start with that kind of story. That's incredible. Thank you for sharing about that. So, as you look toward the company's future and your own, what are you excited about moving forward? [00:20:34] Dhruv Agrawal: I mean, we are currently in the process of getting a new version of our hand in the market, which has all the learnings of the last four years or so. So we are definitely really excited about that. You have to keep in mind when we launched the first product, we didn't even have enough money to-- because prosthetics are expensive-- so we didn't really have had enough money to buy our competitor devices, or the devices from the past to look around to see, touch, feel, how they are built. Everything that we built was purely out of our imagination and based on what we could find on the internet. And, you know, go visit a doctor who fits these devices, have that 10, 15 minutes to look around that device, and so on and so on. I mean, four years later, now we have the experience of fitting close to seven, 800 patients with our device. All that feedback that has gone into the next version product that we are gonna be building. So very excited about that. We continue to develop the software platform, so we are not just a company that is focused on providing a device to the patient, but we provide an entire software platform that's like a digital twin for the patient. So it supports the patients throughout their end-to-end journey. Because it's not just about giving a device to the patient, but it's all about can we improve their quality of life? Can the patient pick up a glass of water? Can he tie his shoelaces? Can he water a plant? Can he do the activities that he really wants to do? And from that perspective, the software platform that we continue to build focuses on things like adherence, occupational therapy, physical therapy, monitoring of the usage of the device. Because the thing in prosthetics industry is, the day you give the device to the patient is not the day you have won the battle. That's the day the battle actually begins, 'cause now it's all about making sure that you deliver on the promise of helping him get better quality of life. [00:22:20] Lindsey Dinneen: Yeah. Yeah. I'm sure that's an exciting challenge, but it's a continually evolving challenge too. And there's probably variations, I would imagine, on people embracing the technology a little bit differently and how you handle all that. Yeah. Excellent. Well that is a very exciting future and it's so much fun to hear about, and you know, you've had a great career so far. I'm sure it's wildly different than what you may have imagined as a kid. But what a cool gift that you're bringing to the world. You've been recognized quite a bit. You're 30 under 30 for Europe, and you've been involved in lots of different cool organizations. You've been a TEDx speaker. What are some of those moments like, have they been surreal? Is it just like, "Oh, thank you." Just confirmation that, hey, you are on the right tracker. What are those kinds of moments like for you? [00:23:08] Dhruv Agrawal: I mean, definitely the first round of funding that we raised in Poland was was a huge check mark for us, because it's that moment at which you realize, "Ah, somebody wants to give me money and somebody wants to give me a quarter of a million dollars." I've never seen that much money together on a single bank account or in any way, shape or form, right? I come from a normal middle class family. We don't have that. So, that was definitely the first micro checkpoint, let's say. I mean, both the things that you mentioned, the TEDx thing, the Forbes 30 Under 30 thing, coming from a background in India where these things are really important, although they're not so important for me as a person, but they're much more important for some reason to my parents and to society. It is a different place. We put a lot of emphasis on these types of things. So from six, seven years ago, looking at these lists coming out or looking at, "Oh, this cool guy spoke on a TEDx talk, sending him an email about, 'Do you want to be an advisor in my company? I'll give you 5% shares,'" and so on and so on, to actually doing those things by yourself, that's definitely pretty well as well. But again, at the end of the day, there is nothing better than seeing a new patient get fitted with the hand, seeing the reaction of their family members. They have a daughter, they have a son who they hold their hand for the first time. They hug their wife. I mean, just, just being around amputees and patients who use your device, something that you built and that helps them get better at their daily life, that's, I would say, the most rewarding thing ever. [00:24:39] Lindsey Dinneen: Yeah, of course. That's, that's wonderful. Yeah. So, oh my goodness, this is so great and very inspirational, but pivoting the conversation a little bit just for fun. Imagine that you were to be offered a million dollars-- speaking of those wonderful sums of money-- to teach a masterclass on anything you want. It can be something within your industry, but doesn't have to be, what would you choose to teach? [00:25:03] Dhruv Agrawal: I have two topics in mind. One is I would probably teach a masterclass on pitching, especially for first time founders. I think that is something which I'm good at, and we have obviously raised a pretty decent amount of capital up 'till now. So that would be the one thing that I would say. So kind of a combination of pitching and starting a startup for the first time, especially in the field of hardware, medical devices, things like that. And the second thing that I would really like to talk about is just probably trying to put my thoughts together and making a masterclass on how to never give up, because I think that that's a very underrated quality. But that's a very important quality. There have been complex times in the history of our company where we have felt that like, "Ah, this might be it." But it's all about what you do in those moments and how you go beyond those. I think it's all about that. [00:25:47] Lindsey Dinneen: Yeah, absolutely. And how do you wish to be remembered after you leave this world? [00:25:53] Dhruv Agrawal: Just as a positive change maker. I really would like all these patients that we are helping and giving these devices to. I, I just want to be a small part of their lives. Just as I was part of the life of the veteran who got married, I, I just wanna ha have those small moments club together amongst these different individuals that we are privileged to work with. [00:26:13] Lindsey Dinneen: Hmm. Yes, of course. Wonderful. And then final question, what is one thing that makes you smile every time you see or think about it? [00:26:22] Dhruv Agrawal: Oh, that's very simple. Patients getting fitted with our device. Today we see a patient getting fitted with our device, and that smile on their face and things like that. And, you know, that's even much bigger, much more interesting in Ukraine because many times when you go to these hospitals, and when I go to these hospitals in Ukraine, you have to understand that these people have gone through a lot. These soldiers who are putting their body on the line for their country. There, of course, there's a certain sort of low morale that they have when they're amputated and when they're in these hospitals and things like that where they don't really think that there is ever a possibility for them to regain something back. And you go in there and you show them a bionic hand, and they're not sure if this thing works, and you put the electrodes on them and they open the hand or close it for the first time, and then you suddenly see those expressions change from like, "Ah, what has happened to me?" to, "Oh, what can I achieve?" That is also an amazing feeling. [00:27:16] Lindsey Dinneen: Yeah. Oh, I love that. What an amazing gift to be able to help somebody bridge that gap and witness it. How cool is that? Oh, well, I think this is incredible. I am so grateful for you and your co-founder for starting this company and just being able to give so many people hope and new life, really, just a new way of experiencing life. So thank you for all of the incredible work you're doing. I'm so excited to continue to follow your work, support your work, as I'm sure all of our listeners are as well. So, gosh, I just really appreciate you sharing all of your advice and stories and wisdom with us. So thanks again so much for being here. [00:27:55] Dhruv Agrawal: Of course, Lindsey, thank so much for having me. [00:27:56] Lindsey Dinneen: Of course, of course. And we are honored to be making a donation on your behalf as a thank you for your time today to the American Society for the Prevention of Cruelty to Animals, which is dedicated to preventing animal cruelty in the United States. We really appreciate you choosing that organization to support and thank you just again, so very much for your time here today. I just wish you continued success as you work to change lives for a better world. And thank you also so much to our listeners, and if you're feeling as inspired as I am right now, I'd love it if you share this episode with a colleague or two and we'll catch you next time. [00:28:43] Ben Trombold: The Leading Difference is brought to you by Velentium. Velentium is a full-service CDMO with 100% in-house capability to design, develop, and manufacture medical devices from class two wearables to class three active implantable medical devices. Velentium specializes in active implantables, leads, programmers, and accessories across a wide range of indications, such as neuromodulation, deep brain stimulation, cardiac management, and diabetes management. Velentium's core competencies include electrical, firmware, and mechanical design, mobile apps, embedded cybersecurity, human factors and usability, automated test systems, systems engineering, and contract manufacturing. Velentium works with clients worldwide, from startups seeking funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

आज से करीब 600 साल पहले एक कवि हुए जो आज तक लोगों के दिलो-दिमाग पर राज करते हैं. नाम है कबीर. कबीर के बारे में यूं तो कई बाते प्रचलित हैं. कुछ का प्रमाण है. कुछ का नहीं. मगर एक बात सौ फीसदी प्रमाणित है कि उनकी बातें अब भी उतनी ही रेलेवेंट हैं. लेकिन कबीर के अलावा और भी कई कवि हुए, जिन्हें अलग अलग कारणों से कबीर जितनी ख़्याति नहीं मिली. इनमें से एक प्रमुख नाम है राजस्थान के संत दादू दयाल का. इन की ख़्याति को यूं समझिए कि उनके समकालीन रहे बादशाह अकबर ने उन्हें उस दौर का कबीर कहा. 40 दिन तक उनसे धार्मिक चर्चा की. मगर ये सब सिर्फ Tip of The Iceberg है. दादू के बारे में जानने को बहुत कुछ है. इसलिए पढ़ाकू नितिन के इस एपिसोड में हमने बात की JNU के पूर्व प्रोफेसर, UPSC के पूर्व मेंबर, न जाने कितनी यूनिवर्सिटियों में पढ़ा चुके और कबीर पर ऑथोरिटी माने वाले Professor Purushottam Agrawal से. प्रोफेसर साहब ने लिखी है दादू के जीवन का समग्र विश्लेषण करती So says Jan Gopal नाम की किताब. उम्मीद है आपको एपिसोड पसंद आएगा. प्रड्यूसर: मानव देव रावत साउंड मिक्स: सूरज सिंह Disclaimer: इस पॉडकास्ट में व्यक्त किए गए विचार एक्सपर्ट के निजी हैं

On Georgetown University's McDonough School of Business Week: A lot of our clothes we buy end up in landfills. Vishal Agrawal, Professor and Henry J. Blommer Family Endowed Chair in sustainable business, looks to reduce this. Vishal Agrawal is Henry J. Blommer Family Endowed Chair in Sustainable Business, Professor of Operations and Information Management, and […]

In this conversation, Abhi Agrawal shares his journey in real estate, focusing on helping homeowners in Texas through creative solutions. He discusses the importance of networking, learning from others, and the challenges of marketing in a competitive environment. Abhi also shares a complex case study of a successful deal he executed, emphasizing the need for persistence and a positive mindset in the real estate industry. Professional Real Estate Investors - How we can help you: Investor Fuel Mastermind:  Learn more about the Investor Fuel Mastermind, including 100% deal financing, massive discounts from vendors and sponsors you're already using, our world class community of over 150 members, and SO much more here: http://www.investorfuel.com/apply   Investor Machine Marketing Partnership:  Are you looking for consistent, high quality lead generation? Investor Machine is America's #1 lead generation service professional investors. Investor Machine provides true ‘white glove' support to help you build the perfect marketing plan, then we'll execute it for you…talking and working together on an ongoing basis to help you hit YOUR goals! Learn more here: http://www.investormachine.com   Coaching with Mike Hambright:  Interested in 1 on 1 coaching with Mike Hambright? Mike coaches entrepreneurs looking to level up, build coaching or service based businesses (Mike runs multiple 7 and 8 figure a year businesses), building a coaching program and more. Learn more here: https://investorfuel.com/coachingwithmike   Attend a Vacation/Mastermind Retreat with Mike Hambright: Interested in joining a “mini-mastermind” with Mike and his private clients on an upcoming “Retreat”, either at locations like Cabo San Lucas, Napa, Park City ski trip, Yellowstone, or even at Mike's East Texas “Big H Ranch”? Learn more here: http://www.investorfuel.com/retreat   Property Insurance: Join the largest and most investor friendly property insurance provider in 2 minutes. Free to join, and insure all your flips and rentals within minutes! There is NO easier insurance provider on the planet (turn insurance on or off in 1 minute without talking to anyone!), and there's no 15-30% agent mark up through this platform!  Register here: https://myinvestorinsurance.com/   New Real Estate Investors - How we can work together: Investor Fuel Club (Coaching and Deal Partner Community): Looking to kickstart your real estate investing career? Join our one of a kind Coaching Community, Investor Fuel Club, where you'll get trained by some of the best real estate investors in America, and partner with them on deals! You don't need $ for deals…we'll partner with you and hold your hand along the way! Learn More here: http://www.investorfuel.com/club   —--------------------

We chat with Material Security about protecting G Suite and MS365. How else are you monitoring the most commonly used cloud environments and applications? In the security news: Google Sues Badbox operators Authenticated or Unauthenticated, big difference and my struggle to get LLMs to create exploits for me Ring cameras that were not hacked Malicous AURs Killing solar farms Weak passwords are all it takes Microsoft's UEFI keys are expiring Kali Linux and Raspberry PI Wifi updates Use lots of electricity, get a visit from law enforcement Sharepoint, vulnerabilities, nuclear weapons, and why you should use the cloud The time to next exploit is short Sonicwall devices are getting exploited How not to vibe code SMS blasters This segment is sponsored by Material Security. Visit https://securityweekly.com/materialsecurity to see purpose-built Google Workspace and Office 365 security in action! Visit https://www.securityweekly.com/psw for all the latest episodes! Show Notes: https://securityweekly.com/psw-884

We chat with Material Security about protecting G Suite and MS365. How else are you monitoring the most commonly used cloud environments and applications? In the security news: Google Sues Badbox operators Authenticated or Unauthenticated, big difference and my struggle to get LLMs to create exploits for me Ring cameras that were not hacked Malicous AURs Killing solar farms Weak passwords are all it takes Microsoft's UEFI keys are expiring Kali Linux and Raspberry PI Wifi updates Use lots of electricity, get a visit from law enforcement Sharepoint, vulnerabilities, nuclear weapons, and why you should use the cloud The time to next exploit is short Sonicwall devices are getting exploited How not to vibe code SMS blasters This segment is sponsored by Material Security. Visit https://securityweekly.com/materialsecurity to see purpose-built Google Workspace and Office 365 security in action! Show Notes: https://securityweekly.com/psw-884

We chat with Material Security about protecting G Suite and MS365. How else are you monitoring the most commonly used cloud environments and applications? In the security news: Google Sues Badbox operators Authenticated or Unauthenticated, big difference and my struggle to get LLMs to create exploits for me Ring cameras that were not hacked Malicous AURs Killing solar farms Weak passwords are all it takes Microsoft's UEFI keys are expiring Kali Linux and Raspberry PI Wifi updates Use lots of electricity, get a visit from law enforcement Sharepoint, vulnerabilities, nuclear weapons, and why you should use the cloud The time to next exploit is short Sonicwall devices are getting exploited How not to vibe code SMS blasters This segment is sponsored by Material Security. Visit https://securityweekly.com/materialsecurity to see purpose-built Google Workspace and Office 365 security in action! Visit https://www.securityweekly.com/psw for all the latest episodes! Show Notes: https://securityweekly.com/psw-884

We chat with Material Security about protecting G Suite and MS365. How else are you monitoring the most commonly used cloud environments and applications? In the security news: Google Sues Badbox operators Authenticated or Unauthenticated, big difference and my struggle to get LLMs to create exploits for me Ring cameras that were not hacked Malicous AURs Killing solar farms Weak passwords are all it takes Microsoft's UEFI keys are expiring Kali Linux and Raspberry PI Wifi updates Use lots of electricity, get a visit from law enforcement Sharepoint, vulnerabilities, nuclear weapons, and why you should use the cloud The time to next exploit is short Sonicwall devices are getting exploited How not to vibe code SMS blasters This segment is sponsored by Material Security. Visit https://securityweekly.com/materialsecurity to see purpose-built Google Workspace and Office 365 security in action! Show Notes: https://securityweekly.com/psw-884

Leading with Integrity: Krati Agrawal's Journey in Amazon and Beyond | Diasporaa Podcast Episode 20 In this episode of Diasporaa, host Aditya Mehta interviews Krati Agrawal, a senior executive in the supply chain industry and a nominee for Marquise Who's Who list for women leaders in technology in the U.S. Krati shares her journey from a small town called Guna in Madhya Pradesh, India, to working at Amazon and now TikTok in the U.S. They discuss her experiences adapting to various American cities, the challenges and benefits of being part of Amazon's Pathways program, and dealing with the stress of visa issues. Krati also touches upon her childhood, family life, and the intricacies of Indian and American cultures. The episode provides an inspiring look at resilience, leadership, and the immigrant experience. List of Resources: Agrawal: https://en.wikipedia.org/wiki/Agrawal Bits Pilani: https://en.wikipedia.org/wiki/BITS_Pilani Goa: https://en.wikipedia.org/wiki/Goa Guna: https://en.wikipedia.org/wiki/Guna_district Ji Mantri Ji: https://en.wikipedia.org/wiki/Ji_Mantriji Kota Factory: https://youtube.com/playlist?list=PLTB0eCoUXErb7pV0Sj1hXWrxerSZX1qgh&feature=shared Madhya Pradesh: https://en.wikipedia.org/wiki/Madhya_Pradesh Marquis Who's Who: https://en.wikipedia.org/wiki/Marquis_Who%27s_Who UPSC: https://en.wikipedia.org/wiki/Union_Public_Service_Commission About the Podcast: Diasporaa was Aditya's third startup based in Vancouver, BC. It focused on helping new immigrants in Canada find their feet, get off to a running start and ease their assimilation into Canadian life. A big part of the platform were conversations, community and support. Though the startup stopped growing once Aditya moved to Seattle, WA - it remained alive in the form of several discussion groups and online communities. Now, Diasporaa has been resurrected in the form of a podcast focused on uncovering and sharing interesting immigrant stories from the South Asian diaspora. It is available on YouTube, all major podcast platforms such as Spotify, Apple Podcasts, Google Podcasts, etc. and is also broadcast as a radio show on Alternative Talk 1150 AM and 98.9 FM HD Channel 3 on Wednesdays from 2-3pm PST. About Aditya Mehta: Aditya is a Bombay boy who has lived in Austin, Los Angeles, Washington DC, and Vancouver before making it to his current home in Seattle. He has degrees in marketing, urban planning, real estate and strategy but has spent his career in financial services, social media and now real estate - mostly as an entrepreneur and partly as an employee at Amazon. He balances Indian, Canadian and American culture, loves helping those who are new to North America and looks forward to the interesting stories that his interview guests bring each week. When not podcasting, he is helping his wife Prachi build her pharmaceutical business or hanging out with his son Arjun. Connect with Diasporaa: -Instagram: @diasporaapodcast -YouTube: https://linke.to/dspyoutube -Bio Link: linke.to/diasporaa -Listen on Spotify: https://linke.to/dspspotify -Listen on Apple Podcasts: https://linke.to/dspapple -Diasporaa Podcast on KKNW Alternative Talk Radio: https://linke.to/kknw1150

Welcome to The Daily Lawyer® Podcast -  and another powerful episode in The General Counsel Series, proudly presented in collaboration with Zoho Sign. Today's guest is Anubhuti Agrawal, Senior Counsel - Development South Asia at Hilton with an impressive career across leading global companies, including Cargill.  With deep legal and leadership experience, Anubhuti brings a refreshing voice to this conversation, where she talks about:  ✅ How the GC role has shifted from oversight to foresight ✅ Building confidence through clarity, not complexity ✅ Why agility, humility, and people skills now matter as much as legal knowledge ✅ What she learned by walking out of a hostile negotiation room ✅ Legal tech, digital signatures, and the real barriers to adoption ✅ Motherhood, mentorship, managing teams, and making lists Whether you're a young lawyer, a seasoned GC, a woman balancing ambition and caregiving, or someone rethinking how law fits into business, this episode will leave you wiser, steadier, and smiling. Connect with us:     Contact: contactus@thedailylawyer.in  Website: https://thedailylawyer.in/   Instagram: https://www.instagram.com/thedailylawyerig/?hl=en   LinkedIn: https://www.linkedin.com/in/jenna-v-krishnan/    Available on Spotify, Apple Podcasts, Google Podcasts and Amazon Music.   Presented in collaboration with Zoho Sign -  A comprehensive e-signature solution built for Indian businesses.   Connect with Zoho Sign:   Instagram: https://www.instagram.com/zohosignofficial/  X: https://x.com/zohosign?lang=en  LinkedIn: https://www.linkedin.com/company/zohosign/  YouTube:   https://www.youtube.com/channel/UCdwgS4wSq0SWx1nWI6ZOdLA  Explore: https://www.zoho.com/sign/  #AnubhutiAgrawal #Hilton #GeneralCounsel #LegalLeadership #TheDailyLawyer #ZohoSign #LegalPodcast #InHouseCounsel #WomenInLaw #LeadershipWisdom #LegalTech

What does it take to build a movement for educational equity? How do you turn young Fellows into changemakers and students into leaders of their own learning?In this special interview, Ankit Agrawal shares his journey from joining Teach For India back in 2015 to leading its mission in Hyderabad today. He talks about the power of student voice, what real leadership looks like in classrooms, and how an entire community can shape the future of education.

How do you adapt when you're in a new place and a new culture? How do you help others adapt? What kind of struggles and challenges will they face, and do we allow them to face them alone? Tune in and find out what we can do to help people adapt in a new culture. Artwork: a.p.e.e.z.y Music by Bensound.com License code: BNAFXH5N0LX38LJO

This isn't the first time we've talked about LinkedIn. But in this episode, we cover specific recommendations for the content you should create and post as well as a proven process for connecting with clients. My guest is content writer Divya Agrawal and what she shared could change your approach to LinkedIn for the better. Click the play button below, or scroll down for a full transcript.   Stuff to check out: The Copywriter Club Facebook Group The Copywriter Underground The How to Write Emotional Copy Masterclass   Full Transcript: Rob Marsh: If you've got enough clients or you're not willing to put yourself out there to find the clients you need, well, you can probably skip this episode. This is The Copywriter Club Podcast. Like last week, we're revisiting a recurring topic on the show this week, but unlike last week, the recurring topics isn't persuasion or psychology. This week we're talking about the biggest challenge facing almost all copywriters and that's finding clients. Even established copywriters will struggle with this from time to time. One of the trusims of business is that if you don't have clients willing to pay you for the work you do, it doesn't matter how good your website is, it doesn't matter how good a writer you are, it doesn't matter that you can solve your client's problems better than anyone else… without the client, you don't have a business. My guest this week is Divya Agrawal, a SaaS and Tech copywriter who has deep experience finding clients on LinkedIn.  Divya started her career as a programmer but quickly figured out she was on the wrong job track, so she switched to writing. The lessons she shares from her experience launching this new business will help any copywriter or content writer who is looking for clients to work with. Specifically, Divya used LinkedIn to create connections with prospects. Her success posting content and making comments on other posts is a model for other writers who want to do the same… and LinkedIn is where a significant number of the people who hire copywriters hangout and connect. If your clients are there, you need to be there too. In this interview, Divya shares the questions she uses to vet her prospects before they become clients, and she outlines exactly how you can connect with clients on LinkedIn yourself. This is informaiton she charges her coaching clients for, but she's sharing much of it today for free. Before we jump into our interview, a little while ago I recorded a masterclass to show copywriters, content writers and other marketers how to write “emotional” copy. Everyone says emotions sell, but how do you actually write emotional copy? I walk through more than a dozen examples in this masterclass and give you a proven process for figuring out the right emotions to focus on as you write… and how they change as you make your pitch. The masterclass includes several bonuses on storytelling, using A.I. to find dominant and transformational emotions, and much more. You can get this masterclass at thecopywriterclub.com/emotion And now, my interview with Divya Agrawal. Divya, welcome to the podcast. I'm excited to hear your story and to talk about how you're finding clients, but tell us, how did you become a freelance copywriter for Tech. Divya Agrawal: Thank you so much for having me on the podcast, Rob, I highly appreciate this chance to talk to you. I have been a big fan of your podcast, so it's really cool that I get to sit here and share what I know. Yeah, I became a freelance tech writer back in 2017 end of 2017 after a year long stint at a IT company as a software engineer, I was a Salesforce developer for a year, and that didn't work out. I did not like the corporate environment. I did not like the work I was doing. So then I was like, I need to do something else. I had always been a writer. So I was one of those kids in school who is asked to write other kids speeches.

What if the student who "won't sit still" or "never starts their work" isn't trying to misbehave—but is quietly asking for support? In this episode, veteran educator Cheryl Agrawal helps us rethink ADHD in the primary classroom. You'll walk away with fresh insights and game-changing strategies that make your school days smoother—for you and your students.In this episode, we'll talk about:What ADHD really looks like in PreK–2 students (it's not just hyperactivity).The overlooked link between reading struggles and inattentive ADHD.Movement and “sensory snacks” that support regulation without disrupting class.How to team up with families and paraprofessionals without feeling overwhelmed.Why small shifts in seating, check-ins, and routines can transform your day.Show LinksPulsehiveCheryl on LinkedIn / InstagramADHD 2.0 Book on AmazonJoin Malia on Instagram.Become a Science of Reading Formula member!Rate, Review, and FollowIf you loved this episode, please take a minute to rate and review my show! That helps the podcast world know that this show is worth sharing with other educators just like you.Scroll to the bottom, tap to rate with five stars, and select "Write a Review". Then let me know what you loved most about the episode!While you're there, be sure to follow the podcast. I'm adding a bunch of bonus episodes to the feed and I don't want you to miss out! 

This week on The Core Report: Weekend Edition, Govindraj Ethiraj speaks with Prateek Agrawal, MD & CEO of Motilal Oswal AMC, overseeing ₹1.5 lakh crore in assets, on why growth investing is outpacing value investing in 2025.As India's equity markets continue to scale new highs, Prateek breaks down the fundamental shifts driving this momentum.He explains why traditional value metrics have become less relevant and how sectors like renewables, EVs, electronics, and defense are becoming key engines of sustainable earnings growth. With inflation low and global interest rates on a downward trend, growth stocks are getting a second wind—especially in India's rapidly evolving, entrepreneur-led economy.For more of our coverage check out ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠thecore.in⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Subscribe to our Newsletter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow us on:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠

If you had millions of people using a product you spent years building, would you kill it?That's exactly what The Browser Company did with Arc.The internet backlash was intense, but cofounders Josh Miller and Hursh Agrawal saw that AI was about to make the web something you talk to, not just click into. The best home for that assistant was the thing that's already between you and the internet—the browser. And they realized they couldn't just duct-tape it on to Arc.One year of heads-down work later, the team launched Dia in beta, and people are raving about it. Dia is a sleek, fast, browser with AI at its core—it gets better with every tab you open, becoming more and more helpful with time. And even though it's still early, Josh and Hursh's big pivot looks like one for the ages.This week on AI & I, Josh and Hursh joined me for their first full-length podcast about their pivot from Arc to Dia. We talk through their decision-making process, the very public backlash the company faced, and the grit it took to stay the course. If you found this episode interesting, please like, subscribe, comment, and share! Want even more?Sign up for Every to unlock our ultimate guide to prompting ChatGPT here: https://every.ck.page/ultimate-guide-to-prompting-chatgpt. It's usually only for paying subscribers, but you can get it here for free.To hear more from Dan Shipper:Subscribe to Every: https://every.to/subscribe Follow him on X: https://twitter.com/danshipper Sponsor: Attio: Go to⁠⁠⁠⁠ https://attio.com/every⁠⁠⁠⁠⁠ and get 15% off your first year on your AI-powered CRM.Timestamps for Spotify:Introduction: 00:01:13The story of how Dan might've been the CEO of The Browser Company: 00:02:47The moment Josh and Hursh knew they had to walk away from Arc: 00:09:42How to handle the weight of the unknown in a pivot: 00:17:08The prototype-driven culture that kept The Browser Company alive: 00:23:31Why having a product loved by millions of users isn't enough :00:25:42The architectural decisions underlying how Dia was built: 00:33:29How Dia almost shipped without its best feature: 00:47:12The best ways people are using Dia in the wild: 00:51:18How Josh and Hursh think about competing with incumbents: 01:07:55How romanticism informs the product decisions behind Dia: 01:17:04Links to resources mentioned in the episode:Hursh Agrawal: @hurshJosh Miller: @joshmMore about Dia: https://www.diabrowser.com/ Writer and investor M.G. Siegler's essay about the AI browser wars: https://spyglass.org/ai-browser-wars/ 

Get more control, greater flexibility, and a path to smarter growth.Gear Up for GrowthWith Jean CaragherFor CPA TrendlinesIn this episode of Gear Up for Growth, powered by CPA Trendlines, Anshul Agrawal, founder of June15 Consulting, shares how direct ownership offshoring is helping CPA firms unlock long-term value and sharpen their competitive edge.  Gear Up for Growth spotlights the best strategies for smart and effficient growth in today's competitive landscape. Gear Up for Growth every Friday here. More Jean Caragher here | Get her best-selling handbook, The 90-Day Marketing Plan for CPA Firms, here | More Gear Up for Growth More CPA Trendlines videos and podcasts here “Direct ownership offshoring is no longer just for the Top 100 firms,” Agrawal explains. “Whether you're a solo practitioner or a mid-sized firm, the model gives you full control of your offshore team without the middlemen – and that changes everything.” According to Agrawal, direct ownership offshoring – where firms directly employ and manage offshore staff – offers a more strategic and cost-effective alternative to traditional outsourcing. It enables firms to maintain independence, expand capacity, and deliver year-round support while improving margins.

In today's episode, I'm so excited to be joined by Meha Agrawal—founder of Silk + Sonder and one of the rare 2% of venture capital-backed female founders.We dive into how Meha turned burnout into a self-care revolution, building a wellness brand that blends journaling, coaching, and community. Her story is honest, inspiring, and packed with practical wisdom for anyone ready to lead with heart and heal from hustle.I trust you will get what you need from this episode, and make sure you come let me know how it resonated with you on instagram @the_human_design_coachBig love,MxxMeha Details:Silk + Sonder24/7 Life CoachingSpecial Offer for 24/7 Life Coaching: Enjoy a 14-day free trial, no credit card required! Plus, you'll get 50% off three months after your 14-day free trial expires.Meha's InstagramMeha's LinkedInBodyGraph Chart SoftwareCreate your own Human Design chart tool with BodyGraphChart! Embed a chart tool on your own website, so you can engage with your leads, grow your business, teach Human Design the way YOU want to teach it and create success!Get BodyGraphChart here: https://bodygraphchart.com?via=emmadunwoodyUse the code humandesignpodcast for 30% off for 6 months!OTHER RESOURCESWant more on Human Design? Explore the ways to get involved below:Get Your Free Human Design Chart: https://www.emmadunwoody.com/get-your-chartThe HDx Collective: https://www.emmadunwoody.com/membershipThe Inner Circle: https://www.emmadunwoody.com/the-inner-circleSupport The Human Design Podcast and your continued learning: https://www.buymeacoffee.com/emmadunwoodyWant to sponsor the podcast? Apply here for the "Millions of Millionaires" project: https://forms.gle/Hs2MGFSuyRrVKJ116Human Design Unhinged: https://www.humandesignunhinged.com/Secret Podcast: The Human Design Podcast (Unhinged): https://thehumandesignpodcast.supercast.com/Instagram @the_human_design_coachMusic: Spark Of Inspiration by Shane Ivers - https://www.silvermansound.comMAGNETIC BY DESIGN MASTERMIND (Starts June 30, USE CODE 888OFF): https://www.emmadunwoody.com/magnetic-by-designSupport the show

Send us a textDhruv Agrawal, founder of Aether Biomedical, shares how a birthday gift 3D printer led him from medical school to developing the Zeus hand, the strongest bionic prosthetic hand on the market with revolutionary cloud-based tracking capabilities.• Journey from medical student to prosthetics innovator began with a 3D printer birthday gift• Uses additive manufacturing not just for prototyping but for actual production components• Zeus hand features industry-leading grip strength and 30-minute repair capability• Cloud-based platform tracks usage data, showing super users complete 700-800 grip cycles daily• Data collected helps optimize device settings and provides evidence for insurance authorization• Most users rely on 4-6 standard grips plus 2-3 customized grips for specific activities• Currently working on multiple versions of the Zeus hand at different price points• Long-term vision is to become "the operating system for assistive devices" across prosthetics, orthotics, and exoskeletons• Company of 60 people with half dedicated to research and development• Future developments include VR training tools for phantom limb pain managementSpecial thanks to Advanced 3D for sponsoring this episode.Support the show

Staying nimble, operationally efficient, and making the best quality beer is key in our current industry.In this webinar, you'll learn how to calculate your true COGS by factoring in WIP losses and final loss, track costs vs. profitability per batch, analyze year-over-year trends for sales, understand tank utilization, and fine-tune your efficiency to keep more money in your pocket.Discover how real-time data tracking, forecasting, and COGS analysis can help your brewery reach higher profitability without sacrificing the quality of your beer.Join Pulkit K. Agrawal, Founder and CEO of Beer30 by The 5th Ingredient, for a look at the brewery KPIs that most brewers miss, resulting in a hit to your bottom line. Staying nimble, operationally efficient, and making the best quality beer is key in our current industry.Learn how to calculate your true COGS by factoring in WIP losses and final loss, track costs vs. profitability per batch, analyze year-over-year trends for sales, understand tank utilization, and fine-tune your efficiency to keep more money in your pocket.In this talk, PK will break down how real-time data tracking, forecasting, and COGS analysis can help your brewery reach higher profitability without sacrificing the quality of your beer.Stay up to date with CBP: http://update.craftbeerprofessionals.org

✨ ¿Alguna vez sentiste que no sabías por dónde empezar? Así comenzó la historia de uno de nuestros invitados en el nuevo episodio de Real Estate Talks.

In this conversation, Host Dr. Riley Kirk and Dr. Anurag Agrawal discuss the intricate relationship between monarch butterflies and milkweed, exploring themes of coevolution, chemical ecology, and the ecological arms race. He explains how monarchs have adapted to survive the toxic compounds in milkweed, the challenges they face due to habitat destruction and pesticides, and the importance of conservation efforts. The discussion highlights the fascinating dynamics of species interactions and the need for community involvement in preserving biodiversity. Chapters 00:00 Introduction to Monarchs and Milkweed 06:32 The Co-evolutionary Dance 11:32 Monarchs vs. Milkweed: The Arms Race 20:14 The Role of Cardiac Glycosides 30:01 Sequestration and Survival Strategies 31:37 The Journey of Monarch Butterflies 37:30 Understanding Monarch Population Decline 46:49 Human Impact on Monarchs and Conservation Efforts 54:01 Exploring Other Fascinating Insects Follow Dr.Agrawal's research: https://ecologyandevolution.cornell.edu/anurag-agrawal https://agrawal.eeb.cornell.edu/ Read or listen to Monarchs and Milkweed https://www.amazon.com/Monarchs-Milkweed-Migrating-Remarkable-Coevolution/dp/0691166358 Preorder my book Reefer Wellness! ⁠⁠https://www.amazon.com/Reefer-Wellness-Understanding-Cannabis-Medicine/dp/0593847156⁠⁠ ✨ Want Exclusive Content? Join the Bioactive Patreon community for as little as $1/month to ask guests your burning questions, access exclusive content, and connect with Dr. Kirk one-on-one.⁠⁠ www.Patreon.com/Cannabichem⁠⁠

“The theme that I found with IPSO [International Psychoanalytical Studies Organization] was that there was a common theme [in psychoanalytic training].  There was an initial phase full of terror and excitement, and then a middle phase of maybe some lethargy or apathy or disillusionment. In that middle phase, many candidates found IPSO, or IPSO found them, where they found refuge. They found solace. They found community, not just at their local institutes, but at this kind of world market. Many of the candidates talk about what a timely and wonderful experience it was to be seen, to be validated by fellow candidates in a way that only fellow candidates can do. At least a couple of the authors have written about how they were delighted to see that more than anything else we are similar as human beings, no matter where we're from.”  Episode Description:  We begin with recognizing the deep attachment that many analytic candidates have about their training experiences, which includes affections and resentments. Himanshu outlines the process of reaching out to candidates globally, inviting them to share their reflections on their journeys. We read from a sampling of their essays that eloquently describe their idealizations and de-idealizations, their delights and their burdens, their profound regard for the mysteries of the mind and the appreciation of the power of psychoanalysis to engage with it. We discuss the importance of IPSO, the difficulties associated with Covid and the relevance of our field's traumatic origins. Himanshu closes with sharing his story of encountering an insightful analytic supervisor during his residency and declaring "I want to be like him." Linked Episode:Episode 89: Wisdom and Enthusiasm for Today's Candidates with Fred Busch, PhD   Our Guest: Himanshu Agrawal, MD is an adult and child psychiatrist and recently completed psychoanalytic training through the Minnesota Psychoanalytic Institute. He is an associate professor of psychiatry and behavioral medicine at the Medical College of Wisconsin in Milwaukee where he sees patients, conducts research, and teaches. He recently completed his term as the president of the candidates' council of the American Psychoanalytic Association Recommended Readings: Busch F (Ed), Dear candidate. Routledge, 2020   Agrawal H,  Trials and Tribulations of being a candidate. The American Psychoanalyst, winter 2022   Kernberg O, Thirty methods to destroy the creativity of psychoanalytic candidates. International Journal of psychoanalysis, 77, 1031- 1040

Guest Suggestion Form: https://forms.gle/bnaeY3FpoFU9ZjA47Disclaimer: This video is intended solely for educational purposes and opinions shared by the guest are his personal views. We do not intent to defame or harm any person/ brand/ product/ country/ profession mentioned in the video. Our goal is to provide information to help audience make informed choices. The media used in this video are solely for informational purposes and belongs to their respective owners.Order 'Build, Don't Talk' (in English) here: https://amzn.eu/d/eCfijRuOrder 'Build Don't Talk' (in Hindi) here: https://amzn.eu/d/4wZISO0Follow Our Whatsapp Channel: https://www.whatsapp.com/channel/0029VaokF5x0bIdi3Qn9ef2JSubscribe To Our Other YouTube Channels:-https://www.youtube.com/@rajshamaniclipshttps://www.youtube.com/@RajShamani.Shorts

Eshaan Agrawal is a Business Analyst at McKinsey & Co. who formerly served in the Office of Technology Transitions at the Department of Energy (DOE). His energy interest is routed in climate impact, and he started off in college by focusing on environmental actions related to air pollution in his local community. Eshaan tells us about why he chose to start his career at DOE rather than alternative options, and then describes the different components of his role, such as authoring the Innovative Grid Deployment Liftoff Report and developing the pathway to commercial liftoff for critical energy transition technologies. Throughout the episode, he shares advice on career decision making, exciting areas of the energy sector, and more.   Keynotes: - Energy work through the government - Figuring out how to maximize impact and make strategic career decisions - Exciting topics within energy And follow us on: Newsletter: https://www.energy-terminal.com/newsletter-signup LinkedIn: https://www.linkedin.com/company/energy-terminal Instagram: https://www.instagram.com/energyterminal/  

Key Learnings/Takeaways: Attendees gained insights from Dr. Agrawal's personal journey, including:The power of "crucible experiences" in shaping leadership skills.Strategies for building a successful coaching practice.The necessity of continuous learning and adapting to change.Essential qualities for effective leadership in today's dynamic environment.The ethical and practical applications of AI within the coaching profession. The discussion also highlighted the significance of self-awareness, trust-building, and embracing vulnerability in both leadership and coaching contexts. If you're passionate about coaching and want to take your skills to the next level, explore Coacharya's range of ICF-accredited training programs. Visit our website for more information! https://coacharya.com/events/ #LeadershipDevelopment #ExecutiveCoaching #CareerAdvice #PersonalDevelopment #HRLeadership #ArtificialIntelligence #CoachEducation #ICFAccreditation #Coacharya #Mastermind #MentorshipThis episode was recorded on 02 April, 2025 as part of the Mastermind Mentor Webinar SeriesYou can watch the recording on our YouTube channel.  If you like this episode, please subscribe to our podcast and connect with us on the links below.  Thank you for your support!Contact Us https://coacharya.com/contactWebsite https://coacharya.comWebinars https://coacharya.com/events/LinkedIn https://www.linkedin.com/company/coacharyaFacebook https://www.facebook.com/CoacharyaTwitter https://twitter.com/coacharyaInstagram https://www.instagram.com/coacharya

Dr. Vamsi Velcheti and Dr. Charu Aggarwal discuss the evolution of ctDNA as a critical tool in precision oncology and its implications for lung cancer management, including its potential role in the early-stage setting. TRANSCRIPT Dr. Vamsi Velcheti: Hello. I am Dr. Vamsi Velcheti, your guest host for the ASCO Daily News Podcast today. I am a professor of medicine and director of thoracic medical oncology at the Perlmutter Cancer Center at NYU Langone Health.  The management of small cell lung cancer has rapidly evolved over the past few decades, and today, molecular testing and biomarker testing for lung cancer are absolutely critical in terms of designing treatment options for our patients with metastatic non-small cell lung cancer. Today, I'm delighted to be joined by Dr. Charu Aggarwal for a discussion on ctDNA (circulating tumor DNA) and the role of ctDNA in lung cancer management. Dr. Aggarwal is the Leslye Heisler Professor of Lung Cancer Excellence and section chief of thoracic and head and neck oncology at University of Pennsylvania Abramson Cancer Center.  You'll find our full disclosures in the transcript of that episode.  Dr. Agrawal, it's great to have you on the podcast today. Thank you for being here. Dr. Charu Aggarwal: Thank you for having me. Dr. Vamsi Velcheti: Let's start off with setting the stage for ctDNA technology. These technologies have rapidly evolved from experimental conceptual stage to essential clinical tools for day-to-day clinical practice. Could you briefly discuss how recent advancements in ctDNA technologies are shaping our approach to precision medicine, especially in lung cancer? Dr. Charu Aggarwal: Absolutely. And you know, I think we need to just level set a little bit. What exactly is circulating tumor DNA? This is a way to assess exactly that. Every tumor sheds little pieces of tumor-derived DNA into the bloodstream, and this occurs in a variety of solid tumors. But now we have the technology to be able to derive this DNA that's actually being shed from the tumor into the bloodstream, these minute fragments of DNA, take them out, amplify them and sequence them with a variety of different mechanisms. They can be DNA sequencing alone, they can be DNA and RNA sequencing, they can be whole transcriptome sequencing. The technology, as you rightly pointed out, Dr. Velcheti, has significantly improved from just being able to look at circulating tumor DNA to now being able to amplify it, sequence it, and use it to offer personalized therapy. I think lung cancer is definitely the poster child for such an approach as we have a lot of data that has shown clinical utility and validity of being able to use circulating tumor DNA next-generation gene sequencing to guide therapy. Dr. Vamsi Velcheti: There have been so many technological leaps. It's really impressive how far we've come to advance these sequencing platforms. Recent advances with AI and machine learning are also playing important roles in interpreting ctDNA data. How are these computational advances really enhancing clinical decision-making in day-to-day clinical practice? Dr. Charu Aggarwal: I think while we have firmly established the role of ctDNA in the management of patients with metastatic lung cancer, some of the approaches that you talked about are still experimental. So let me backtrack a little bit and set the stage for how we use ctDNA in clinical practice right now. I think most patients, when they come in with a new diagnosis of stage IV lung cancer, we want to test for biomarkers. And this should actually be the established standard. Now included in the NCCN guidelines and actually also international guidelines, is to consider using blood-based testing or plasma-based testing to look for biomarkers, not just tissue-based testing which had been our historical standard, but to use these plasma guided approaches to identify the seven to nine biomarkers that may be truly implicated in either first- or second-line therapy that are called as your immediately actionable mutations.  What you're talking about is AI computational methods. I think there's a lot of excitement about how we can use genomic signatures that are derived from either tissue or ctDNA-based biomarker testing, combine it with radiomic features, combine it with histologic features, look at H & E patterns, use AI algorithmic learning to be able to actually predict recurrence scores, or can we actually come up with predictive signatures that may be extremely helpful?  So, I think some of the techniques and technologies that you're talking about are incoming. They are provocative. I think they're very exciting, but very early. Dr. Vamsi Velcheti: I think it's really amazing how many advances we have with these platforms. You know, the challenge really is the significant gap in terms of uptake of molecular testing. Even today, in 2025, there are significant gaps in terms of all metastatic lung cancer patients being tested for all biomarkers.  So, why do you think there's such a challenge in testing patients with lung cancer? In most academic practices, we try to achieve 100% testing for all our patients, but we know from recent studies that that's not the case across the country. What do you think the gaps are? Dr. Charu Aggarwal: Biomarker testing is so essential, like you pointed out, for us to be able to guide the right therapy for our patients. And we see this in our practice every day as you and I see patients with lung cancer, that a large proportion of our patients either don't get tested or they start therapy before their test results come back. So, I think this is a real problem.  However, to add some optimism to this problem, I do think that we are making a move in the right direction. So, four or five years ago, there was a lot of data being presented at national meetings, including ones from the American Society of Clinical Oncology, where we saw that, nationally, the rates of biomarker testing were probably in the rate of 40 to 50%. However, now with the availability of both tissue and plasma, I do think that the rates of biomarker testing are increasing. And if you were to survey a sample or even perform retrospective data research, I believe that the number is closer to 70% of all patients with metastatic non-small cell lung cancer.  And you know, you asked why is it not 100%? I think there are many reasons. I think the number one reason is tissue availability. Many times, the biopsies are small, or the tumor is very necrotic. So, either the tissue quantity itself is small, or the tissue quantity is insufficient to perform gene sequencing. And that's exactly where plasma comes in. When you don't have tissue availability, we have shown, as have others, that you can use plasma effectively to increase the proportion of patients who are not only tested but also receive the right therapy. I think there are also other barriers, including inertia. You know, I think this is both patient and physician inertia, where patients want to get started quickly, they don't want to wait. Physicians are very busy and sometimes want to be able to deliver treatment as soon as possible. We have seen there are some institutional barriers. Not every institution has in-house gene sequencing testing. So how do you really operationalize, send out these tests in a fast, efficient manner so that you get results back? Is it a pathologist who sends out the test? Is it the medical oncologist? Is it the pulmonologist or the interventionalist? I think there is this need to develop reflex testing mechanisms which some institutions do really well and some don't. And then finally, there are financial implications as well. How do we do this in a most cost-efficient fashion?  So there are many barriers, but I'm happy to say that we are making a move in the right direction as we are understanding that it's important to do it, it's easy to do it maybe with a value add of plasma, and finally, as you said, you know, as these technologies become more available, they're actually getting more cost-effective. Dr. Vamsi Velcheti: Dr. Aggarwal, you've been at the cutting edge of these advanced platforms and testing. So, what do you do in UPenn? How do you handle all these barriers and what is your workflow for patients in University of Pennsylvania? Dr. Charu Aggarwal: One of the things that I mentioned to you was there may be institutional barriers when it comes to gene sequencing. So, we actually, several years ago now, instituted a very robust reflex testing paradigm where almost all of our patients, regardless of stage, with a non-squamous non-small cell lung cancer diagnosis, would automatically be reflexively sent to our molecular pathology lab where they would get gene sequencing both for the DNA as well as with an RNA fusion-based platform. And the reason we did this was because we wanted to expedite and reduce the turnaround time. We also wanted to ensure that we were not just doing DNA testing, which I think is really important for our listeners here. There are many fusions as well as certain skipping mutations like MET exon 14 that may be missed on DNA testing alone. So, it's really incredibly important to run both DNA and RNA samples.  So, we do this routinely, and based on our research and others, what we also do routinely is that we send concurrent tissue and liquid biopsies or plasma MGS testing upon initial diagnosis. For example, if a patient comes in with a diagnosis of stage IV non-small cell lung cancer, their tissue might already be at my molecular pathology lab based on the reflex mechanism that I just described to you. But upon their initial meeting with me, we will send off plasma. And I will tell you this, that Penn is not just one institution, right? We have a large network of sites. And as part of my research, one of the things that we wanted to do was implement wide scale means to improve biomarker testing. And we have done this with the use of technology like you mentioned, Dr. Velcheti: How can we actually use AI? How can we leverage our electronic medical record to identify these patients? So, we have a nudge-based mechanism which actually facilitates the pending of orders for biomarker testing for patients with new diagnosis of metastatic non-small cell lung cancer. And we are looking at our rates of biomarker testing but also rates of completion of biomarker testing before first-line therapy started. So many of our participating sites are clusters for our randomized control trial to increase molecular testing. And I'm really excited about the fact that we're able to implement it not just at our main satellite, downtown Penn Hospital, but also across our community. Dr. Vamsi Velcheti: I think that's great. Thank you so much for those insights, Dr. Aggarwal. I think it's so important because having the best technology is just not enough. I think implementation science is actually a real thing. And I think we need to all learn from each other, advance these things.  So, I want to ask you about the new emerging paradigm in terms of using ctDNA. Of course, in the metastatic setting, we've been using ctDNA for molecular profiling for a while now. But the recent data around monitoring early-stage disease, especially post-operative monitoring, is an exciting area. There are a lot of opportunities there. Could you please talk us through the emerging data in lung cancer and how do we incorporate ctDNA-based monitoring MRD or should we even do that right now? Is the data ripe enough for us to kind of deploy this in a clinical setting? Dr. Charu Aggarwal: I think using ctDNA in the early-stage setting is our next frontier in lung cancer. I think naturally we have been able to successfully deploy this in the stage 4 setting. It made a meaningful difference in the lives of our patients, and we are a little bit behind the A ball in terms of how MRD is used in lung cancer. Because, you know, colorectal cancer has already done large-randomized trials based on ctDNA and MRD. It's routinely used in hematological malignancy. So, it makes sense that we should start to use it.  However, when I say this, I say this with excitement, but also a little bit of gentle caution saying that we actually don't quite have the prospective randomized data just yet on how to deploy. Yes, intuitively we would say that if you detect ctDNA and MRD, that patient is at higher risk. So, we identify that, but we actually don't know what to do with the second part of that information once you identify a patient with high risk. Are there other techniques that we can then come in with or other drugs that we can come in with to modify that risk? And that's the thing that I think we don't have right now. The other thing that we don't have right now is the timing of the assay, when to use it. Is it to be tested in the pre-op setting? Is the post-op test the best timing, or is it monitoring and dynamics of ctDNA that are most important? And the third thing I will say in terms of precautionary cause is that we don't know which test just yet. There are actually a few commercially available tests out in the market right now. We know about them and I'm sure our community colleagues know about them. Some of them even have Medicare approval. However, many of these tests are currently tissue informed. We don't have tissue uninformed tests. And what does that mean? Tissue uninformed means that you actually take a piece of tumor tissue, you sequence that tumor and based on the gene profile of that tumor, you actually design a panel that can then be used to track the mutations in the blood-based pack. This requires, as the name implies, a tumor. So can this be used in the pre-op setting is a large question. Because coming back to the idea of tissue availability, you and I both know that when we get FNAS and we use it for PDL-1 testing and we use it for gene sequencing, there often isn't enough tissue left for us to then either do whole genome sequencing or even whole transcriptome sequencing, which may be required to build some of these assays.  I think the future lies in this idea of tumor uninformed assays because if we could go to a blood only or a plasma only approach using novel signatures like proteomics or methylation, I think that's where the future is. But we're still a little bit early in the discovery stages of those, as well as to come are the validation stages so that we can be confident that these blood-only assays may actually give us an answer.  So, with those three cautionary notes, I would say that optimism is still very high. I think ctDNA MRD is the right place to think about. We need to do this for our patients to better identify high-risk patients and to think about means to escalate treatment for them. Dr. Vamsi Velcheti: Yeah, I completely agree, and I think with all the changes and evolution of treatments in the management of early-stage lung cancer now with neoadjuvant and adjuvant, there's really a need for an escalation and de-escalation of therapies post-operatively. And I think it's a huge opportunity. I think we all could learn from our colorectal colleagues. I think they've done a really good job at actually doing prospective trials in this setting. I think we're kind of a little behind here.  Dr. Charu Aggarwal: I think in the metastatic setting there are ongoing trials to look at this exact question. How do you choose an appropriate first-line therapy, a monitor ctDNA at the six-week trial? It's being evaluated in a trial called the “Shedders” trial, where if patients are still ctDNA positive at six weeks, then you can escalate treatment because they haven't “cleared” their ctDNA. There has been a lot of research that has shown that lack of ctDNA clearance in the metastatic setting may be a poor prognostic factor. We and others have shown that if you do clear your ctDNA or if you have a reduction in ctDNA load overall, that that is directly related to both an improved progression-free survival and overall survival. This has been shown with both tissue informed and uninformed assays. So I think it's very clear that yes, you can track it. I think the question is: Can you apply that data to the early-stage setting? And that's an open research question. A lot of groups are looking at that and I think it's completely reasonable, especially to determine duration of therapy, to determine optimal timing, optimal timing of scans even. And I think these are just such interesting questions that will be answered in the future. Dr. Vamsi Velcheti: And also like a kind of early detection of resistance patterns that might inform early initiation of combination strategies. And I think it's a lot of opportunities I think yet to be explored. A lot of exciting things to come and I'm sure we'll kind of see more and more data in the next few years.  Dr. Aggarwal, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been a pleasure to have you on the podcast today. Hope to see you at ASCO. Dr. Charu Aggarwal: Thank you so much. This was great and I remain so excited by all of the possibilities to improve outcomes for our patients. Dr. Vamsi Velcheti: Thank you to all the listeners for your time today. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcast. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Follow today's speakers:  Dr. Vamsidhar Velcheti  @VamsiVelcheti  @vamsivelcheti.bsky.social Dr. Charu Aggarwal @CharuAggarwalMD   Follow ASCO on social media:  @ASCO on X (formerly Twitter)  ASCO on Bluesky ASCO on Facebook  ASCO on LinkedIn    Disclosures: Dr. Vamsidhar Velcheti:  Honoraria: Glavanize Therapeutics Consulting or Advisory Role: Bristol-Myers Squibb, Merck, AstraZeneca/MedImmune, GSK, Amgen, Taiho Oncology, Novocure, Takeda, Janssen Oncology, Picture Health, Regeneron Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline  Dr. Charu Aggarwal: Consulting or Advisory Role: AstraZeneca, Daiichi Sankyo/AstraZeneca, Regeneron/Sanofi, Pfizer, Boehringer Ingelheim, Takeda, Arcus Biosciences, Gilead Sciences, Novocure, Abbvie Speakers' Bureau: AstraZeneca (an immediate family member) Research Funding (Inst): Merck Sharp & Dohme, AstraZeneca/MedImmune, Daiichi Sankyo/AstraZeneca, Lilly@Loxo, Candel Therapeutics  

Major traumatic brain injury is a huge issue for Paediatric Intensive Care. We have machines for almost every organ: but the brain is on its own. Shruti Agrawal, consultant in paediatric intensive care in Addenbrookes Hospital, Cambridge, is first author on the Starship study, recently published in the Lancet eClinical […]

Consensus is slow by design.In crypto, we've accepted the tradeoff: robustness at the cost of speed. Whether it's proof-of-work or proof-of-stake, every node reprocesses every transaction, every time. It's secure and reliable... but often overkill for most of what we actually do.What if we stopped treating every transaction like a global event? What if the base layer didn't have to decide who bought a coffee first, especially when those transactions have nothing to do with each other?Pod Network offers an alternative closer to a network of local agreements, where state can move fast, stay composable, and only invoke ordering when absolutely necessary.We sat down with Shresth Agarwal at ETHDenver to talk about rethinking onchain design. If you've ever thought about the limits of blockspace, MEV, or how far we can push latency while keeping decentralization intact, this conversation is going to give you something new to think about. Join The Rollup Edge: https://members.therollup.coWebsite: https://therollup.co/Spotify: https://open.spotify.com/show/1P6ZeYd..Podcast: https://therollup.co/category/podcastFollow us on X: https://www.x.com/therollupcoFollow Rob on X: https://www.x.com/robbie_rollupFollow Andy on X: https://www.x.com/ayyyeandyJoin our TG group: https://t.me/+8ARkR_YZixE5YjBhThe Rollup Disclosures: https://therollup.co/the-rollup-discl

In this episode, Dr. Shantanu Agrawal, Chief Health Officer at Elevance Health, discusses the company's innovative approach to addressing social determinants of health. He highlights the Elevance Health Foundation's new impact investing program, its focus on behavioral health, and how insurers can drive meaningful change in communities.

In this episode, Dr. Shantanu Agrawal, Chief Health Officer at Elevance Health, discusses the company's innovative approach to addressing social determinants of health. He highlights the Elevance Health Foundation's new impact investing program, its focus on behavioral health, and how insurers can drive meaningful change in communities.

Join Emily's brand-new Embodied Manifesting Course Ziva Magic - get 15% off with promo code WHYTHIS: https://zivameditation.com/magic What if capitalism wasn't just about profit—but about purpose? In this episode of Why Isn't Everyone Doing This?, I sit down with the legendary Miki Agrawal—serial entrepreneur, disruptor, and the creator of multiple 9-figure businesses—to unpack the game-changing concept of Conscious Capitalism. Miki has built brands that challenge norms (from period underwear to bidets to sustainable diapers) and has proven that business can be wildly profitable and make a real impact. She shares how to scale with integrity, lead with soft power, and create brands that people are obsessed with.

In this episode of PodRocket, Dev Agrawal, dev advocate and developer, talks about building efficient asynchronous UIs, the challenges and solutions for handling complex state management, utilizing React and Solid frameworks, and the potential of suspense boundaries and transitions in modern web development. Links https://devagr.me https://github.com/devagrawal09 https://www.linkedin.com/in/dev-agrawal-88449b157 https://medium.com/@devagrawal09 https://www.youtube.com/channel/UCDXzM8ijdxkVA6NbQiQCKag https://x.com/devagrawal09 https://events.codemash.org/2025CodeMashConference#/agendaday=4&lang=en&sessionId=76186000004278631&viewMode=2 We want to hear from you! How did you find us? Did you see us on Twitter? In a newsletter? Or maybe we were recommended by a friend? Let us know by sending an email to our producer, Emily, at emily.kochanekketner@logrocket.com (mailto:emily.kochanekketner@logrocket.com), or tweet at us at PodRocketPod (https://twitter.com/PodRocketpod). Follow us. Get free stickers. Follow us on Apple Podcasts, fill out this form (https://podrocket.logrocket.com/get-podrocket-stickers), and we'll send you free PodRocket stickers! What does LogRocket do? LogRocket provides AI-first session replay and analytics that surfaces the UX and technical issues impacting user experiences. Start understand where your users are struggling by trying it for free at [LogRocket.com]. Try LogRocket for free today.(https://logrocket.com/signup/?pdr) Special Guest: Dev Agrawal.

On this episode Doug speaks with Mitesh Agrawal the CEO of Positron.ai. Positron is advancing the world of AI hardware right here in the Biggest Little City, with their first product that provides 3X the performance of NVIDA at a lower cost. They discuss the changing landscape of AI, the importance of purpose built hardware and Positrons unique value. They discuss the Positron team, their investors and their success to date as well as dive in the future for them in our region.

Mauli Agrawal is the chancellor of the University of Missouri-Kansas City. He joined KCUR's Up To Date for the series "5 Questions" to discuss music, books and the state of Kansas City.

In this episode, CJ is joined by Kapil Agrawal, CFO at Outschool, former CFO of Poshmark, and former Global Head of Pricing and Finance Business Partner at Uber. Kapil shares insights on Uber's pricing strategies and the use of promotions to drive customer growth. He discusses the multiple North Star metrics used at Uber before explaining his role in changing the company's take rate. He also talks about his role at Poshmark and how he raised the company's gross margin. The conversation explores the advantages and challenges of marketplace models versus subscription models and highlights the potential of combining both. Also covered is the significance of high-quality decision-making as a leader and the role of hard work in achieving this.—SPONSORS:MUFG is the largest bank in Japan and a global banking powerhouse with a focus on empowering Growth and Middle Market stage companies in North America and Europe. MUFG provides comprehensive banking services for VC-backed, PE-backed, and public companies with revenues starting at $40M. The bank combines its global capabilities with deep operational understanding to help companies accelerate their growth trajectory. Contact group head Bob Blee at bblee@us.mufg.jp to find out more.Brex offers the world's smartest corporate card on a full-stack global platform that is everything CFOs need to manage their finances on an elite level. Plus they offer modern banking and treasury as well as intuitive expenses and accounting automation, bill pay, and travel. Brex makes it easy to control spend before it happens, automate annoying tasks, and optimize your finances. Find out how Brex can help you make every dollar count at brex.com/metrics.Vanta's trust management platform takes the manual work out of your security and compliance process and replaces it with continuous automation. Over 9000 businesses use it to automate compliance needs across over 35 frameworks like SOC 2 and ISO 27001. Centralize security workflows, complete questionnaires up to five times faster, and proactively manage vendor risk. For a limited time, get $1,000 off of Vanta at vanta.com/metrics.Tropic is an intelligent spend management solution that consolidates your spend data and processes into one unified offering, enabling insights and decisive action. It doesn't just show you where the problems are—it helps you solve them. From spotting hidden optimization opportunities, like duplicative spend, to automating those painful procurement workflows, to giving you the best market data that turns every vendor negotiation in your favor. Tropic combines smart insights with real human expertise to keep you ahead of the curve. Visit tropicapp.io/mostlymetrics to learn how.RightRev automates the revenue recognition process from end to end, gives you real-time insights, and ensures ASC 606 / IFRS 15 compliance—all while closing books faster. Whether it's multi-element arrangements, subscription renewals, or complex usage-based contracts, RightRev takes care of it all. That means fewer spreadsheets, fewer errors, and more time for your team to focus on growth. For modern revenue recognition simplified, visit rightrev.com and schedule a demo.Planful is a financial performance management platform designed to streamline financial tasks for businesses. It helps with budgeting, closing the books, and financial reporting, all on a cloud-based platform. By improving the efficiency and accuracy of these processes, Planful allows businesses to make better financial decisions. Find out more at www.planful.com/metrics.—FOLLOW US ON X:@cjgustafson222 (CJ)—TIMESTAMPS:(0:00) Preview and Intro(02:50) Sponsor – MUFG | Brex | Vanta(07:15) Discounting and Promotions at Uber(09:26) Pros and Cons of Acquiring Customers with Promotions(13:48) How Uber Determined the Promotion Term of Nine Months(14:33) Promotional Launch Strategies Across Different Uber Platforms(17:49) Sponsor – Tropic | RightRev | Planful(21:10) The Multiple North Star Metrics at Uber(24:31) Retention for Drivers Versus Passengers(25:25) Tackling the Competition for Drivers(27:20) Changing Uber's Take Rate(31:55) Raising the Gross Margins at Poshmark(37:53) Moving from Buyer and Seller Cohorts to User Cohorts(39:20) Poshmark's Take Rate(42:46) Intro to Outschool(43:20) Transaction-Based Models Versus Subscription-Based Models(45:04) The Role of Capital Allocation(47:22) Combining Transaction-Based and Subscription-Based Models(49:45) Being Judged on the Quality of Your Decisions(54:00) Hiring: Generalists Versus Specialists(56:06) Long-Ass Lightning Round: A Price Cut Regret(57:34) Advice to Younger Self(58:44) Finance Software Stack(59:28) Craziest Expense Story Get full access to Mostly metrics at www.mostlymetrics.com/subscribe

What are psychedelics? How do they impact your brain? Are they safe? Parker and Emma unpack the current research and legality of psychedelics and discuss the ethical implications of psychoactive drugs. Sources: Cheung, K., Earp, B. D., Patch, K., & Yaden, D. B. (2025). Distinctive But Not Exceptional: The Risks of Psychedelic Ethical Exceptionalism. The American Journal of Bioethics, 25(1), 16–28. Tiwari, P., Davoudian, P. A., Kapri, D., Vuruputuri, R. M., Karaba, L. A., Sharma, M., … Vaidya, V. A. (2024). Ventral hippocampal parvalbumin interneurons gate the acute anxiolytic action of the serotonergic psychedelic DOI. Neuron, 112(22), 3697-3714. Wang, E., Mathai, D. S., Gukasyan, N., Nayak, S., & Garcia-Romeu, A. (2024). Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. Healthcare Professionals. Scientific Reports, 14(1), 28022. Davis, A. K., Bates, M., Lund, E. M., Sepeda, N. D., Levin, A. W., Armstrong, S. B., … Yehuda, R. (2024). The Epidemiology of Psychedelic Use Among United States Military Veterans. Journal of Psychoactive Drugs, 1–14. Published Online. September 12, 2024. Ehrenkranz, R., Agrawal, M., Nayak, S. M., & Yaden, D. B. (2024). Adverse events should not be surprising in psychedelic research. Psychedelic Medicine. Published Online. September 4, 2024. Hinkle, J. T., Graziosi, M., Nayak, S. M., & Yaden, D. B. (2024). Adverse events in studies of classic psychedelics. JAMA Psychiatry, 81(12), 1225-1235. Yaden, D. B., Goldy, S. P., Weiss, B., & Griffiths, R. R. (2024). Clinically relevant acute subjective effects of psychedelics beyond mystical experience. Nature Reviews Psychology, 3(9), 606–621. Goldy, S. P., Hendricks, P. S., Keltner, D., & Yaden, D. B. (2024). Considering distinct positive emotions in psychedelic science. International Review of Psychiatry, 1–12. Published Online. September 2, 2024. Heller, N. H. & Barrett, F. S. (2024). Teaching a new dog old tricks: bringing rigor, grounding, and specificity to psychedelic neuropsychopharmacology. Neuropsychopharmacology. Published Online. August 26, 2024. Yaden, D. B., Mathai, D., Bogenschutz, M., & Nichols, D. E. (2024). The pharmacology of hallucinogens. In: Miller et al. (Eds.). Principles of Addiction Medicine. American Society of Addiction Medicine. Yaden, D. B., Nayak, S. M., Griffiths, R. R. (2024). Belief change and agnostic frames in psychedelic research and clinical contexts. In: C. Letheby (Ed.). Philosophy and the psychedelic renaissance. Oxford University Press, New York. DiRenzo, D., Barrett, F. S., Perin, J., Darrah, E., Christopher-Stine, L., & Griffiths, R. R. (2024). Impact of psilocybin on peripheral cytokine production. Psychedelic Medicine, 2(2). Cheung, K., Propes, C., Jacobs, E., Earp, B. D., & Yaden, D. B. (2024). Psychedelic group-based integration: Ethical assessment and initial recommendations. International Review of Psychiatry, 1–11. Tiwari, P., Ehrenkranz, R., & Yaden, D. B. (2024). Psychiatric Applications of Psychedelics: Neurobiological Foundations for Treatments of Depression, Anxiety, and Obsessive-Compulsive Disorder. Advances in Psychiatry and Behavioral Health. McGuire, A. L., Cohen, I. G., Sisti, D., Baggott, M., Celidwen, Y., Devenot, N., Gracias, S., Grob, C., Harvey, I., Kious, B., Marks, M., Mithoefer, M., Nielson, E., Öngür, D., Pallas, A., Peterson, A., Schenberg, E. E., Summergrad, P., Waters, B., Williams, M. T., & Yaden, D. B. (2024). Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement. JAMA Network Open, 7(6), e2414650.

Sanjay Agrawal is a visionary leader and the Executive Director at Ramesh Corp., a prominent company making significant strides in multiple industries in Nepal. With a keen eye on innovation and market trends, Sanjay is dedicated to steering the company toward a future of growth and diversification.

This episode is sponsored by Netsuite by Oracle, the number one cloud financial system, streamlining accounting, financial management, inventory, HR, and more.   NetSuite is offering a one-of-a-kind flexible financing program. Head to  https://netsuite.com/EYEONAI to know more.  In this episode of the Eye on AI podcast, we dive into the transformative world of AI compute infrastructure with Mitesh Agrawal, Head of Cloud/COO at Lambda   Mitesh takes us on a journey from Lambda Labs' early days as a style transfer app to its rise as a leader in providing scalable, deep learning infrastructure. Learn how Lambda Labs is reshaping AI compute by delivering cutting-edge GPU solutions and accessible cloud platforms tailored for developers, researchers, and enterprises alike.   Throughout the episode, Mitesh unpacks Lambda Labs' unique approach to optimizing AI infrastructure—from reducing costs with transparent pricing to tackling the global GPU shortage through innovative supply chain strategies. He explains how the company supports deep learning workloads, including training and inference, and why their AI cloud is a game-changer for scaling next-gen applications.   We also explore the broader landscape of AI, touching on the future of AI compute, the role of reasoning and video models, and the potential for localized data centers to meet the growing demand for low-latency solutions. Mitesh shares his vision for a world where AI applications, powered by Lambda Labs, drive innovation across industries.   Tune in to discover how Lambda Labs is democratizing access to deep learning compute and paving the way for the future of AI infrastructure.   Don't forget to like, subscribe, and hit the notification bell to stay updated on the latest in AI, deep learning, and transformative tech! Stay Updated: Craig Smith Twitter: https://twitter.com/craigss Eye on A.I. Twitter: https://twitter.com/EyeOn_AI (00:00) Introduction and Lambda Labs' Mission (01:37) Origins: From DreamScope to AI Compute Infrastructure (04:10) Pivoting to Deep Learning Infrastructure (06:23) Building Lambda Cloud: An AI-Focused Cloud Platform (09:16) Transparent Pricing vs. Hyperscalers (12:52) Managing GPU Supply and Demand (16:34) Evolution of AI Workloads: Training vs. Inference (20:02) Why Lambda Labs Sticks with NVIDIA GPUs (24:21) The Future of AI Compute: Localized Data Centers (28:30) Global Accessibility and Regulatory Challenges (32:13) China's AI Development and GPU Restrictions (39:50) Scaling Lambda Labs: Data Centers and Growth (45:22) Advancing AI Models and Video Generation (50:24) Optimism for AI's Future (53:48) How to Access Lambda Cloud  

In this episode of Gradient Dissent, Akshay Agrawal, Co-Founder of Marimo, joins host Lukas Biewald to discuss the future of collaborative AI development. They dive into how Marimo is enabling developers and researchers to collaborate seamlessly on AI projects, the challenges of scaling AI tools, and the importance of fostering open ecosystems for innovation. Akshay shares insights into building a platform that empowers teams to iterate faster and solve complex AI challenges together.Follow Weights & Biases:https://twitter.com/weights_biases https://www.linkedin.com/company/wandb Join the Weights & Biases Discord Server:https://discord.gg/CkZKRNnaf3

In this podcast, we dive into the revolutionary world of Inhabitr with our special guest, Ankur Agrawal, the visionary founder of the first fully integrated platform-as-a-service furniture company. Discover how Inhabitr is redefining furnishing with flexible subscription, purchase, and pre-owned options across sectors like hospitality, multifamily housing, staging, student housing, short-term rentals (STR), and direct-to-consumer markets. Learn how their platform leverages AI-powered technology and a proprietary supply chain to provide a wide variety of furniture options curated by in-house designers. We also discuss their impressive achievement of raising a total of $31 million, including $27 million in Series B funding from Hamilton Ventures. Ankur Agrawal also shares his personal journey, relocating from Chicago, where he had a successful career at McKinsey & Company, to Silicon Valley to pursue his dream. Headquartered in San Francisco and Mumbai, Inhabitr is transforming the furniture rental industry with innovative and affordable solutions. Tune in to hear Ankur's insights on innovation, entrepreneurship, and the future of flexible furnishing solutions!

How will the incoming Trump administration handle challenges in China, the Middle East, Russia and Ukraine? Join Major as he goes around the world with the editor-in-chief of Foreign Policy, Ravi Agrawal. This episode was recorded on November 22, 2024.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Medsider Radio, we sat down with Dhruv Agrawal, CEO of Aether Biomedical. Aether's ZEUS bionic arm is a highly durable, multi-articulating prosthetic designed to handle everyday tasks with improved grip strength and resilience.Dhruv found his true calling in building prosthetics while he was studying medicine and proceeded to co-found Aether when he was 18. Since starting Aether, he has helped raise over $15 million in funding and guided the launch of the ZEUS bionic hand, now deployed worldwide, including those impacted by the war in Ukraine.In this interview, Dhruv discusses the importance of defining a clear problem statement, his approach to using grants to supplement VC funding, and the lessons he's learned about evaluating market opportunities while operating globally.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ lifescience investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VI. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Dhruv Agrawal.

Celebrating Powerhouse Women salutes and recognizes women who are making an impact, whether it's in business, philanthropy, public service, or elsewhere. Amita Agrawal McClain/My Easy School Supply Amita Agrawal McClain, the Founder of My Easy School Supply, was born and raised in Nepal and now lives in Duluth, GA. She wanted to make a difference […] The post Amita Agrawal McClain, Founder of My Easy School Supply appeared first on Business RadioX ®.

Social media during election season? Yeah, it's a lot, right?

It's hard to escape talk of AI these days, but not all AI is the same, and not all of it is safe for large organizations to use. Today we're diving into the evolving world of generative AI for the enterprise with Sumeet Agrawal, VP of Product Management at Informatica. We'll discuss strategies and considerations for building robust, enterprise-grade generative AI applications. Sumeet Kumar Agrawal is a VP of Product Management at Informatica. Based in the Bay Area, Sumeet has 15+ years of data engineering and product management experience, driving innovative products within the cloud technology sector. He leads the Cloud AI/GenAI, Analytics & Data warehouse & Data lake, and iPaaS product portfolio at Informatica. It consists of multiple product lines such as Cloud Data Engineering, Streaming, big data, NoSQL, Serverless, Cloud Mass Ingestion(including CDC), Serverless & AI/ML, GenAI, API, and App Integration initiatives. He has a lot of experience working with many cloud ecosystem vendors like AWS, GCP, Azure, Snowflake, Databricks, etc. Apart from this, Sumeet has been frequently recognized as a strong communicator who has successfully worked with people from broad socio-economic backgrounds, and diverse cultures, building strong and fruitful organizational teams. He sits on the advisory board of many startups. RESOURCES Informatica website: https://www.informatica.com Register for the Medallia CX Day webinar: Building Loyalty: How Top Brands Create Forever Customers with CX - https://bit.ly/3M7dkQM Connect with Greg on LinkedIn: https://www.linkedin.com/in/gregkihlstrom Don't miss a thing: get the latest episodes, sign up for our newsletter and more: https://www.theagilebrand.show Attend the Mid-Atlantic MarCom Summit, the region's largest marketing communications conference. Register with the code "Agile" and get 15% off. Register now for HumanX 2025. This AI-focused event which brings some of the most forward-thinking minds in technology together. Register now with the code "HX25p_tab" for $250 off the regular price. Check out The Agile Brand Guide website with articles, insights, and Martechipedia, the wiki for marketing technology: https://www.agilebrandguide.com The Agile Brand podcast is brought to you by TEKsystems. Learn more here: https://www.teksystems.com/versionnextnow The Agile Brand is produced by Missing Link—a Latina-owned strategy-driven, creatively fueled production co-op. From ideation to creation, they craft human connections through intelligent, engaging and informative content. https://www.missinglink.company Learn more about your ad choices. Visit megaphone.fm/adchoices

Paulina Rowinska is a writer, mathematician and science communicator, whose new book, Mapmatics: How We Navigate the World Through Numbers, tells the stories found within crunching tricky equations. Rowinska has a PhD in Mathematics of Planet Earth from Imperial College London and across the pages of Mapmatics she explores fields ranging from map-making to forecasting elections, how we get our packages delivered on time and even how mathematics can be used to prevent crime. Joining her to discuss it is Roma Agrawal, MBE, who is a structural engineer, author and broadcaster. Agrawal has written three books, the most recent of which is Nuts & Bolts, which was shortlisted for the 2023 Royal Society Science Book Prize. Her new children's book, Seven Small Inventions that Changed the World, is out in late August. Find out more at www.Romatheengineer.com. We are sponsored by Indeed. Go to Indeed.com/IS for £100 sponsored credit. If you'd like to become a Member and get access to all of our longer form interviews and Members-only content, just visit intelligencesquared.com/membership to find out more. For £4.99 per month you'll also receive: - Full-length and ad-free Intelligence Squared episodes, wherever you get your podcasts - Bonus Intelligence Squared podcasts, curated feeds and members exclusive series - 15% discount on livestreams and in-person tickets for all Intelligence Squared events - Our member-only newsletter The Monthly Read, sent straight to your inbox ... Or Subscribe on Apple for £4.99: - Full-length and ad-free Intelligence Squared podcasts - Bonus Intelligence Squared podcasts, curated feeds and members exclusive series ... Already a subscriber? Thank you for supporting our mission to foster honest debate and compelling conversations! Visit intelligencesquared.com to explore all your benefits including ad-free podcasts, exclusive bonus content and early access. ... Subscribe to our newsletter here to hear about our latest events, discounts and much more. https://www.intelligencesquared.com/newsletter-signup/ Learn more about your ad choices. Visit podcastchoices.com/adchoices

Newt talks with Professor Ajay Agrawal, a key player in the world of Artificial Intelligence and author of Power and Prediction: The Disruptive Economics of Artificial Intelligence. Agrawal discusses the rapid evolution of AI, highlighting the significant advancements made in the last decade. He explains that AI's core function is to improve prediction, but it also requires human clarity for value judgments within those predictions. Agrawal also discusses the potential for AI to dramatically increase productivity and trigger a large reallocation of capital. He predicts that AI will force society to be more explicit about value judgments and trade-offs, leading to increased transparency.See omnystudio.com/listener for privacy information.